SXTP vs. EQ, LPTX, EDSA, BIVI, AFMD, UBX, PRPH, INAB, IPA, and CLDI
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Equillium (EQ), Leap Therapeutics (LPTX), Edesa Biotech (EDSA), BioVie (BIVI), Affimed (AFMD), Unity Biotechnology (UBX), ProPhase Labs (PRPH), IN8bio (INAB), ImmunoPrecise Antibodies (IPA), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.
60 Degrees Pharmaceuticals vs.
Equillium (NASDAQ:EQ) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
Equillium received 35 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 80.00% of users gave Equillium an outperform vote while only 5.00% of users gave 60 Degrees Pharmaceuticals an outperform vote.
Equillium has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 3.41, suggesting that its share price is 241% more volatile than the S&P 500.
60 Degrees Pharmaceuticals has a net margin of 0.00% compared to Equillium's net margin of -10.05%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Equillium's return on equity.
In the previous week, Equillium had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 4 mentions for Equillium and 3 mentions for 60 Degrees Pharmaceuticals. Equillium's average media sentiment score of 0.29 beat 60 Degrees Pharmaceuticals' score of 0.22 indicating that Equillium is being referred to more favorably in the media.
27.0% of Equillium shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 30.3% of Equillium shares are held by company insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Equillium currently has a consensus target price of $3.00, indicating a potential upside of 610.90%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than 60 Degrees Pharmaceuticals.
Summary
Equillium beats 60 Degrees Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SXTP) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy SXTP Stock Free SXTP Stock Alerts